We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-11.1%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$55.3M
AUM Growth
-$12.3M
Cap. Flow
-$3.77M
Cap. Flow %
-6.81%
Top 10 Hldgs %
62.56%
Holding
65
New
2
Increased
18
Reduced
1
Closed
10

Top Buys

Rank Stock Value
1
FBIO icon
Fortress Biotech
FBIO
+$595K
2
AMRN
Amarin Corp
AMRN
+$297K
3
UTHR icon
United Therapeutics
UTHR
+$282K
4
ALKS icon
Alkermes
ALKS
+$253K
5
REGN icon
Regeneron Pharmaceuticals
REGN
+$64.5K

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$868K
2
SRPT icon
Sarepta Therapeutics
SRPT
+$813K
3
BLUE
bluebird bio
BLUE
+$743K
4
INSM icon
Insmed
INSM
+$690K
5
PCRX icon
Pacira BioSciences
PCRX
+$489K

Sector Composition

Rank Sector Weight
1 Healthcare 54.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
IBB icon
1
iShares Biotechnology ETF
IBB
$9.23B
$12.4M 22.48%
125,000
– –
IBB icon
2
CALL
iShares Biotechnology ETF
IBB
$9.23B
$8.46M 15.28%
85,000
– –
LABU icon
3
Direxion Daily S&P Biotech Bull 3X ETF
LABU
$617M
$3.09M 5.58%
4,993
+71
+1% +$59K
MTD icon
4
Mettler-Toledo International
MTD
$26.5B
$2.28M 4.12%
3,235
– –
BMY icon
5
Bristol-Myers Squibb
BMY
$124B
$1.67M 3.02%
33,000
– –
SGEN
6
DELISTED
Seagen Inc. Common Stock
SGEN
$1.54M 2.78%
18,020
+119
+0.7% +$8.72K
ILMN icon
7
Illumina
ILMN
$28.2B
$1.44M 2.6%
4,853
+22
+0.5% +$6.49K
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$123B
$1.4M 2.54%
8,279
+86
+1% +$15.2K
IONS icon
9
Ionis Pharmaceuticals
IONS
$8.99B
$1.21M 2.18%
20,124
– –
ALNY icon
10
Alnylam Pharmaceuticals
ALNY
$35.7B
$1.1M 1.99%
13,684
+333
+2% +$26.3K
ALXN
11
DELISTED
Alexion Pharmaceuticals
ALXN
$973K 1.76%
9,933
+6
+0.1% +$676
QGEN icon
12
Qiagen
QGEN
$8.49B
$951K 1.72%
27,215
– –
ONCE
13
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$941K 1.7%
9,699
– –
FBIO icon
14
Fortress Biotech
FBIO
$112M
$865K 1.56%
40,903
+25,301
+162% +$595K
PRQR icon
15
ProQR Therapeutics
PRQR
$240M
$798K 1.44%
138,461
– –
INCY icon
16
Incyte
INCY
$23.4B
$791K 1.43%
10,659
+46
+0.4% +$3.72K
EXAS
17
DELISTED
Exact Sciences
EXAS
$771K 1.39%
8,534
– –
REGN icon
18
Regeneron Pharmaceuticals
REGN
$70.9B
$677K 1.22%
2,439
+218
+10% +$64.5K
BMRN icon
19
BioMarin Pharmaceuticals
BMRN
$11.5B
$654K 1.18%
9,700
+300
+3% +$23.1K
DCPH
20
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$632K 1.14%
18,631
– –
ASND icon
21
Ascendis Pharma A/S
ASND
$17.1B
$596K 1.08%
6,190
– –
QURE icon
22
uniQure
QURE
$2.77B
$560K 1.01%
14,215
– –
CELG
23
DELISTED
Celgene Corp
CELG
$559K 1.01%
5,625
– –
CRSP icon
24
CRISPR Therapeutics
CRSP
$4.71B
$542K 0.98%
13,214
– –
EPZM
25
DELISTED
Epizyme, Inc
EPZM
$520K 0.94%
50,378
– –
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return
ACP
Aquiline Capital Partners New York $46.9M AUM 5.65% 1-Year Est. Return

Opus Point Partners Management's Q3 2019 Portfolio in Review

As of Q3 2019, Opus Point Partners Management held 65 positions worth $55.3M, down 18% from $67.6M the previous quarter. Its ten largest holdings account for 63% of the portfolio.

Opus Point Partners Management withdrew a net $3.77M in Q3 2019, closing 10 positions and reducing 1 holding. Its most notable exit was Immunomedics Inc, an estimated $868K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 55% of assets, down from 56% a quarter earlier.

Against the trend, Opus Point Partners Management opened a new position in United Therapeutics worth $279K.

  • Opus Point Partners Management's largest Q3 2019 buy was United Therapeutics: 3,498 shares worth $279K.
  • Opus Point Partners Management added most to Fortress Biotech in Q3 2019, an estimated $595K increase.
  • Opus Point Partners Management's biggest Q3 2019 reduction was Intercept Pharmaceuticals, Inc., cutting an estimated $131K.
  • Opus Point Partners Management fully exited Immunomedics Inc in Q3 2019, selling an estimated $868K.
  • Opus Point Partners Management's ten largest holdings make up 63% of its $55.3M portfolio in Q3 2019.
  • Opus Point Partners Management opened 2 new positions and closed 10 in Q3 2019.
  • Opus Point Partners Management's portfolio value fell 18% quarter-over-quarter to $55.3M.

Based on Opus Point Partners Management's 13F filing for Q3 2019, filed 14 Nov 2019.